David F. Crawford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David F. Crawford has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Amel Hassan
Centre for Immunodeficiency, Molecular Immunology Unit, UCL Institute of Child Health, London, United Kingdom
1 shared publication - Andrew R. Gennery
Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK
1 shared publication - Arjan C. Lankester
Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, the Netherlands
1 shared publication - Christopher C. Dvorak
Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation University of California San Francisco San Francisco California USA
1 shared publication E. Scott Helton
Departments of ‡Cell Biology, ∥Genetics, §Pediatrics, and ¶School of Medicine, University of Alabama, Birmingham, Alabama 35233
1 shared publicationHanumantha R. Pokala
Jimmy Everest Section of Pediatric Hematology-Oncology and Bone Marrow Transplant, Oklahoma University Health Science Center, Oklahoma City, OK
1 shared publication
Latest Publications
- 28 April 2017
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (9)
A novel homozygous VPS45 p.P468L mutation leading to severe congenital neutropenia with myelofibrosis
VPS45‐associated severe congenital neutropenia (SCN) is a rare disorder characterized by life‐threating infections, neutropenia, neutrophil and platelet dysfunction, poor response to filgrastim, and myelofibrosis with extramedullary hematopoiesis. We present a patient with SCN due to a homozygous c.1403C>T (p.P468L) mutation in VPS45, critical regulator of SNARE‐dependent membrane fusion. Structural modeling indicates that P468, like the T224 and E238 residues affected by previously reported mutations, cluster in a VPS45 “hinge” region, indicating its critical role in membrane fusion and VPS45‐associated SCN. Bone marrow transplantation, complicated by early graft failure rescued with stem cell boost, led to resolution of the hematopoietic phenotype.
- 28 April 2017
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (9)
A novel homozygous VPS45 p.P468L mutation leading to severe congenital neutropenia with myelofibrosis
VPS45‐associated severe congenital neutropenia (SCN) is a rare disorder characterized by life‐threating infections, neutropenia, neutrophil and platelet dysfunction, poor response to filgrastim, and myelofibrosis with extramedullary hematopoiesis. We present a patient with SCN due to a homozygous c.1403C>T (p.P468L) mutation in VPS45, critical regulator of SNARE‐dependent membrane fusion. Structural modeling indicates that P468, like the T224 and E238 residues affected by previously reported mutations, cluster in a VPS45 “hinge” region, indicating its critical role in membrane fusion and VPS45‐associated SCN. Bone marrow transplantation, complicated by early graft failure rescued with stem cell boost, led to resolution of the hematopoietic phenotype.
- 17 October 2016
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (6)
Voriconazole‐induced hepatotoxicity following the administration of PEG‐asparaginase: Case report
- 17 October 2016
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (6)
Voriconazole‐induced hepatotoxicity following the administration of PEG‐asparaginase: Case report
- 1 October 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (4) , 935-943.e15
Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency
- 1 October 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (4) , 935-943.e15
Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency
- Open Access
- 1 August 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (32) , 22304-22315
G2E3 Is a Dual Function Ubiquitin Ligase Required for Early Embryonic Development
- 1 August 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (32) , 22304-22315
Open AccessG2E3 Is a Dual Function Ubiquitin Ligase Required for Early Embryonic Development